{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:15:34Z","timestamp":1767705334334},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1016\/j.critrevonc.2004.05.002","type":"journal-article","created":{"date-parts":[[2004,7,30]],"date-time":"2004-07-30T05:37:42Z","timestamp":1091165862000},"page":"1-7","source":"Crossref","is-referenced-by-count":15,"title":["Variations in \u201crescuability\u201d of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development"],"prefix":"10.1016","volume":"52","author":[{"given":"Mercedes","family":"Rodr\u0131\u0301guez-Calvillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Inog\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ascensi\u00f3n","family":"L\u00f3pez-D\u0131\u0301az de Cerio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Zabalegui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Bendandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2004.05.002_BIB1","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/BF02986612","article-title":"Immunotherapy for lymphomas","volume":"77","author":"Timmerman","year":"2003","journal-title":"Int. J. Hematol"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1586\/14737140.1.1.65","article-title":"Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma","volume":"1","author":"Bendandi","year":"2001","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB3","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1073\/pnas.69.6.1540","article-title":"Myeloma proteins as tumor-specific transplantation antigens","volume":"69","author":"Lynch","year":"1972","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB4","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.140.6.1547","article-title":"Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice","volume":"140","author":"Sugai","year":"1974","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB5","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJM199210223271705","article-title":"Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors","volume":"327","author":"Kwak","year":"1992","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB6","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V89.9.3129","article-title":"Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma\u2014long-term results of a clinical trial","volume":"89","author":"Hsu","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB7","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/13928","article-title":"Complete molecular remissions induced by patient-specific vaccination plus granulocyte\u2013monocyte colony-stimulating factor against lymphoma","volume":"5","author":"Bendandi","year":"1999","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB8","first-page":"400","article-title":"Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma","volume":"87","author":"Barrios","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB9","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1182\/blood.V88.2.580.bloodjournal882580","article-title":"Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin\u2019s lymphoma","volume":"88","author":"Nelson","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB10","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.4049\/jimmunol.159.4.1885","article-title":"DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C","volume":"159","author":"Spellerberg","year":"1997","journal-title":"J. Immunol"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1089\/hum.1997.8.10-1287","article-title":"A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92\/33. Protocol NO: PH1\/027a","volume":"8","author":"Hawkins","year":"1997","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB12","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/3266","article-title":"DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma","volume":"4","author":"King","year":"1998","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB13","first-page":"5845","article-title":"Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma","volume":"62","author":"Timmerman","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB14","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1046\/j.1365-2141.2003.04698.x","article-title":"Anti-idiotype vaccines","volume":"123","author":"McCarthy","year":"2003","journal-title":"Br. J. Haematol"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB15","first-page":"578","article-title":"A phase I\/II trial to evaluate the immunogenicity of recombinant idiotype protein vaccines for the treatment of non-Hodgkin\u2019s lymphoma (NHL)","volume":"96","author":"Timmerman","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0022-1759(86)90032-3","article-title":"Mouse \u00d7 human heterohybridomas as fusion partners with human B cell tumors","volume":"89","author":"Carroll","year":"1986","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB17","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1023\/A:1012586905273","article-title":"Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers","volume":"12","author":"Bendandi","year":"2001","journal-title":"Ann. Oncol"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB18","first-page":"1438","article-title":"Feasibility of idiotype vaccination in relapsed B-cell malignancies","volume":"88","author":"Inoges","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB19","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European\u2013American classification of lymphoid neoplasm: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB20","first-page":"358a","article-title":"Idiotype vaccine and dose-adjusted EPOCH-Rituximab treatment in untreated mantle cell lymphoma: preliminary report on clinical outcome and analysis of immune response","volume":"102","author":"Wilson","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB21","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1182\/blood.V78.12.3275.3275","article-title":"All advanced stage non-Hodgkin\u2019s lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment","volume":"78","author":"Gribben","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB22","first-page":"357a","article-title":"Recombinant idiotype-KLH vaccination (MyVax\u2122) following CHOP chemotherapy in mantle cell lymphoma","volume":"102","author":"Leonard","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1073\/pnas.96.2.703","article-title":"Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants","volume":"96","author":"McCormick","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB24","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1182\/blood.V95.4.1342.004k19_1342_1349","article-title":"Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells","volume":"95","author":"Osterroth","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB25","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood.V99.7.2562","article-title":"Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma","volume":"99","author":"Zhu","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2141.2003.04064.x","article-title":"Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt\u2019s lymphoma and mucosa-associated lymphoid tissue lymphoma","volume":"120","author":"Zhu","year":"2003","journal-title":"Br. J. Haematol"},{"key":"10.1016\/j.critrevonc.2004.05.002_BIB27","first-page":"541","article-title":"Acquized potential N-glycosylation within the tumor-specific immunoglobin heavy chains of B-cell malignancies","volume":"89","author":"Zabalegui","year":"2004","journal-title":"Haematologica"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084280400085X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084280400085X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T03:26:03Z","timestamp":1682738763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084280400085X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["S104084280400085X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2004.05.002","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}